Member Highlights - Biweekly newsletter of the International Cytokine & Interferon Society

Member highlight – Rami Bechara

November 12, 2023

Rami Bechara
Pharm.D; Ph.D
Assistant Professor
Université Paris-Saclay, Paris, France [READ MORE]

Member highlight – Curt Horvath

November 8, 2023

Curt M. Horvath, Ph. D. ; Professor in the Department of Molecular Biosciences, Northwestern University, Evanston, Illinois, USA X:@JakStatMan [READ MORE]

Joaquin Espinosa enjoying a hike in the woods

Member Highlight: Meet Joaquin M. Espinosa, Ph.D.

March 31, 2025

My team investigates the impacts of interferon hyperactivity and immune dysregulation in Down syndrome. We are testing the hypothesis that immune dysregulation drives many of the clinical and developmental hallmarks of Down syndrome. There is now a vibrant community of immunologists studying Down syndrome, and I believe that attending the [READ MORE]

New Member Mini-Bios

New Member Mini-Bio: Chen Yao, Ph.D., University of Texas Southwestern Medical Center

March 31, 2025

Dr. Chen Yao is an assistant professor in the Department of Immunology at UT Southwestern Medical Center. Having earned her Ph.D. from the University of Minnesota under the guidance of Dr. Daniel Kaplan, Dr. Yao furthered her expertise through postdoctoral training in the systems immunology laboratory led by Dr. John [READ MORE]

Early Interferon-beta Treatment for West-Nile Virus Infection

March 31, 2025

ClinicalTrials.gov ID NCT06510426 Sponsor Tel-Aviv Sourasky Medical Center Study Overview – Brief Summary West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease. Despite that, in minority of cases (~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease). [READ MORE]

Safety and Efficacy of Interferon-Gamma 1b in Patients with Candidemia

March 31, 2025

ClinicalTrials.gov ID NCT04979052 Sponsor Radboud University Medical Center Study Overview – Brief Summary A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patients with candidemia. Detailed Description A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety [READ MORE]

Interferon Alpha Therapy for Cervical CINI and HPV Infection

March 31, 2025

ClinicalTrials.gov ID NCT06137950 Sponsor Mongolian National University of Medical Sciences Study Overview – Brief Summary Mongolia is a traditionally nomadic and population is scarce in rural areas. Thus, the medical care service is not sufficient. In 2000, Mongolian government has developed and implemented the millennium project in cooperation with WHO. [READ MORE]

Share this:

Share this: